A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)

Binder M, Meyer O, Rummel M, Nimmerjahn F, Tesanovic T, Sauer T, Matzdorff A (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Oncology Research and Treatment Karger Publishers

Publisher: KARGER

City/Town: BASEL

Pages Range: 166-167

Conference Proceedings Title: ONCOLOGY RESEARCH AND TREATMENT

Authors with CRIS profile

Falk Nimmerjahn Lehrstuhl für Genetik

Involved external institutions

Universitätsklinikum Halle (Saale) DE Germany (DE) Charité - Universitätsmedizin Berlin DE Germany (DE) Universitätsklinikum Gießen und Marburg (UKGM) DE Germany (DE) Novartis AG CH Switzerland (CH) Asklepios Klinikum Uckermark (AKU) DE Germany (DE)

How to cite

APA:

Binder, M., Meyer, O., Rummel, M., Nimmerjahn, F., Tesanovic, T., Sauer, T., & Matzdorff, A. (2021). A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP). In ONCOLOGY RESEARCH AND TREATMENT (pp. 166-167). BASEL: KARGER.

MLA:

Binder, M., et al. "A Phase II study to investigate the efficacy and safety of eltrombopag in combination with dexamethasone compared to dexamethasone as first-line treatment in adult patients with newly diagnosed primary ITP (XPAG-ITP)." Proceedings of the ONCOLOGY RESEARCH AND TREATMENT BASEL: KARGER, 2021. 166-167.

BibTeX: Download